Quantcast
Last updated on April 24, 2014 at 12:48 EDT

Latest ViroPharma Incorporated Stories

2012-08-06 06:26:39

CHICAGO, Aug. 6, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Google Inc. (Nasdaq:GOOG), Yahoo Inc (Nasdaq:YHOO), Microsoft (Nasdaq:MSFT), ViroPharma Incorporated (Nasdaq:VPHM) and Halozyme Therapeutics (Nasdaq:HALO). (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO) Get...

2012-08-01 10:26:33

EXTON, Pa., Aug. 1, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that ViroPharma and Halozyme Therapeutics were notified by the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration that FDA is evaluating potential safety concerns with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20). Although FDA did not disclose the specific concerns due to their confidentiality requirements, Halozyme informed...

2012-07-27 06:21:39

EXTON, Pa., July 27, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the publication of data demonstrating that routine prophylactic use of Cinryze® (C1 esterase inhibitor [human]) provided effectiveness and maintained a generally favorable safety profile in the majority of treated subjects with hereditary angioedema (HAE). HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of a human plasma protein called C1...

2012-07-24 14:22:25

EXTON, Pa., July 24, 2012 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2012 are expected to be released no later than Thursday, August 9, 2012. In light of the August 9th PDUFA date for industrial scale expansion of Cinryze® (C1 esterase inhibitor [human]), the company has chosen to align the two events. In the event the company receives a response from the FDA prior to August 9th, the company will announce the specific timing of the...

2012-07-13 06:24:24

PHILADELPHIA, July 13, 2012 /PRNewswire/ -- The law firm of Berger & Montague, P.C. was the first law firm to file a class action against Viropharma Incorporated and Vincent J. Milano in Eastern District of Pennsylvania on May 17, 2012, Docket Number 2:12-CV-02714 on behalf of all investors who purchased shares of Viropharma ("VPHM") between December 14, 2011 and April 9, 2012. The complaint alleges that on December 14, 2011 Viropharma issued a press release announcing the...

2012-07-03 06:25:33

EXTON, Pa., July 3, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Colin Broom, MD, vice president and chief scientific officer of ViroPharma, will present at the 2012 JMP Securities Healthcare Conference at 11:00 A.M. ET on Thursday, July 12, 2012. The conference is being held at the Peninsula Hotel in New York City. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the...

2012-06-04 10:22:46

PHILADELPHIA, June 4, 2012 /PRNewswire-USNewswire/ --On May 17, 2012 the law firm of Berger & Montague, P.C. filed a class action Complaint against ViroPharma Incorporated (VPHM)"("ViroPharma" or the "Company") and Vincent J. Milano, its President, Chief Executive Officer and Chairman of its Board of Directors, in the Eastern District of Pennsylvania, No. 2:12-CV-02714 on behalf of all purchasers of ViroPharma securities between December 14, 2011 and April 9, 2012, inclusive (the "Class...

2012-06-04 02:25:36

EXTON, Pa., June 4, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients. The planned program will consist of two independent Phase 2 clinical studies that will include subjects at different ends of the spectrum of CMV infection or disease, namely those who have asymptomatic CMV, and those who have failed therapy with other anti-CMV agents....

2012-05-25 10:23:12

LOS ANGELES, May 25, 2012 /PRNewswire/ -- The Lin Law Firm, A Professional Law Corporation, announces that a class action has been filed on behalf of investors who purchased the securities of ViroPharma Incorporated ("ViroPharma") (Nasdaq:VPHM) between December 14, 2011 and April 9, 2012 ("Class Period"). The Complaint asserts violations of the federal securities laws against ViroPharma and its Chief Executive Officer, Vincent Milano. For more information on the class action, please contact...

2012-05-22 06:25:43

EXTON, Pa., May 22, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Goldman Sachs 2012 Healthcare Conference at 8:00 P.M. PT (11:00 A.M ET) on Tuesday, June 5, 2012. The conference is being held at the Terranea Resort in California. ViroPharma also announced that William Roberts, vice president, corporate communications will present at the Jefferies & Company...